• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Vaqta
    / MSD


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 Vial x 25 U/0.5 ml

    not in the basket chart

    Vial

    1 Vial x 50 U/ml

    not in the basket chart 66549 22179

    Indications

    Active pre-exposure prophylaxis against disease caused by Hepatitis A virus in persons 2 years and older. Primary immunization should be given at least 2 weeks prior to expected exposure to HIV.
    See prescribing information for full details.


    Contra-Indications

    Hypersensitivity to any component of the vaccine.


    Special Precautions

    Will not prevent hepatitis caused by infectious agents other than hepatitis A virus, bleeding disorders in people who are at risk of hemorrhage, acute infection or febrile illness, pregnancy and lactation.


    Side Effects

    No serious vaccine-related adverse experiences were observed during clinical trials.


    Drug interactions

    None reported.


    Manufacturer
    Merck Sharp & Dohme B.V., Haarlem, Holland
    CLOSE